Eight of the nine boys registered to date in the new trial are alive and well, with functioning immune systems and free of infections associated with SCID-X1, between nine and 36 months following treatment, according to Sung-Yun Pai, MD, a pediatric hematologist-oncologist from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She presented the findings at the 55th annual meeting of the American Society of Hematology on behalf of the Transatlantic Gene Therapy Consortium (TAGTC). The investigators continue to monitor the children for signs of treatment-associated leukemia, which developed three to five years post-treatment in the prior trial. They point to surrogate biological markers that give them hope the viral vector used to deliver the new treatment is safe.
"These results show that the new vector appears to retain efficacy and, at least in preliminary studies, may be safer," said David A. Williams, MD, a leader of Dana-Farber/Boston Children’s, who is chief of the Division of Hematology/Oncology at Boston Children’s Hospital, associate chair of pediatric oncology at Dana-Farber Cancer Institute, and principal investigator for the gene therapy trial’s U.S. sites.
Of the eight patients, seven are actively producing T cells, which are critical components of a healthy immune system. Six of these seven have met the trial’s primary endpoint: a T-cell count greater than 300 cells per microliter of blood and T-cell proliferation in response to stimulation with phytohemagglutinin. The one patient among the seven who is producing T cells but has not yet achieved 300 cells/microliter will receive a second round of gene therapy next month.
The eighth surviving patient underwent a cord blood stem cell transplant after the gene therapy treatment failed to stimulate T-cell production. The lone fatality was caused by an overwhelming adenovirus infection present at the time the child entered the trial.
At the heart of the trial is a self-inactivating vector used to ferry the gene for the IL-2 receptor gamma subunit (IL2RG) into a patient’s hematopoietic (blood-forming) stem cells. Once the gene is inserted, the cells are returned to the patient. IL2RG fuels the development and growth of immune cells and is a key component of normal immune system development. In children born with SCID-X1, the gene carries a mutation that renders it inactive.
The viral vector used in the study is a modified gammaretrovirus, a member of a family of viruses able to insert genetic cargo into the genome of mammalian cells and drive expression of the inserted genes. The vector has been engineered to avoid the leukemia that halted the previous SCID-X1 gene therapy effort.
Analyses of T cells from the participants in the current trial suggest that the new vector avoided genomic sites known to contribute to leukemia development. The study team will continue to keep a close eye on the patients for any signs of abnormal T-cell growth.
"Our preliminary data suggest that this new vector approach appears to be as effective as the previous vector, and may avoid the long-term risk of leukemia," said Pai. "We are closely monitoring the patients to evaluate their long-term risks, but the excellent responses we have seen thus far give us hope."
"This study represents a unique approach to international collaboration by leading pediatric researchers to quickly address the previous adverse events caused by gammaretrovirus-based vectors," Williams said. "Working together, this group of scientists did the basic studies needed to develop and test a new vector, guide the new trial through a complicated regulatory review process and begin quickly enrolling patients."
The study’s U.S. sites are supported by the National Institute of Allergy and Infectious Diseases (grant number U01AI087628) and the National Heart Lung and Blood Institute’s Product Assistance for Cellular Therapies Program.
source : http://www.sciencedaily.com/releases/2013/12/131208090337.htm